Clinical Trials Update: Jan. 16, 2007
Tuesday, January 16, 2007; 12:00 AM
(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:
Cervical Dysplasia or Human Papilloma Virus (HPV)
REPORTER'S QUERY The Washington Post is looking for challenging medical cases--ones that have been resolved but in which the patient's symptoms were puzzling to doctors or suggested an immediate diagnosis that would have been wrong.
Patients must have medical records documenting their care, and must be willing to share them with a reporter. Please include day and evening phone numbers and an e-mail address. E-mail medicalmysteries@washpost.com with your name and details. Please put "Medical Mystery" in the subject line.In Depth
AIDS/HIVVirus that causes AIDS passes between U.S. and Mexico. 
Young Lives at RiskExplore the epidemic of childhood obesity, and learn what's being done to stop it. 
All About PlasticsPlastics changed our world. But are we trading safety for convenience? 
Staph InfectionsThe latest patient information on methicillin-resistant staph infections and how to avoid them.
 
Your Co-Workers Like McSteamy?
We can help you find the right work environment with competitive benefits. Nursing, Allied Health: Get a New Job
|
Have you recently had an abnormal pap test or been told that you have cervical HPV (human papillomavirus)? If so, you may qualify for an investigational study to evaluate the eradication of HPV infection after using an investigational gel applied intravaginally. Women 18-45 who are willing to be on an acceptable method of birth control, have a screening pap test of low-grade squamous intraepithelial lesions (LSIL) or atypical squamous cells of undetermined significance (ASC-US), and are high-risk HPV positive may qualify. The study will last approximately 27 months and involve up to 16 clinic visits.
The research sites are located throughout the United States and Canada.
More information
Please see http:/
-----
Alzheimer's Disease
This study will test the effectiveness of the study medication as an add-on therapy to current Alzheimer's medication. Volunteers 50-90 who have a probable diagnosis of Alzheimer's disease and have been receiving at least six months of ongoing treatment for Alzheimer's may be included. Patients must have a caregiver who is willing to attend all visits, oversee patient compliance, and report on patient status. Participants may not be diagnosed with vascular dementia, or have a history of any other CNS disorder (stroke, hemorrhage, epilepsy, Parkinson's, etc.). Other criteria apply.
The research site is in Little Rock, Ark.
More information
Please see http:/
